Journal article icon

Journal article

Lessons learned from HIV-1 vaccine trials: new priorities and directions.

Abstract:
A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/ni.2264

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Experimental Medicine Division,
Role:
Author
Journal:
Nature immunology
Volume:
13
Issue:
5
Pages:
423-427
Publication date:
2012-05-05
DOI:
EISSN:
1529-2916
ISSN:
1529-2908
URN:
uuid:97a88f02-d203-47ee-99b4-334daec5f38a
Source identifiers:
325203
Local pid:
pubs:325203

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP